

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13D  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

NEUROCRINE BIOSCIENCES, INC.  
(Name of Issuer)

COMMON STOCK, .001 PAR VALUE  
(Title of Class of Securities)

64125C109  
(CUSIP Number)

Dr. Herbert Gut  
Ciba-Geigy Limited  
Klybeckstrasse 141  
CH-4002, Basle  
Switzerland  
41-61-696-1111

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

MAY 31, 1996  
(Date of Event which Requires  
Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ] .

Check the following box if a fee is being paid with this statement [X]. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of less than five percent of such class. See Rule 13d-7.)

-----  
 CUSIP NO. 64125C109  
 -----

-----  
 Page 2 of 9 Pages  
 -----

-----  
 1 NAME OF REPORTING PERSON  
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Ciba-Geigy Limited

-----  
 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) / /  
 (b) /x/

-----  
 3 SEC USE ONLY

-----  
 4 SOURCE OF FUNDS\*

WC

-----  
 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO / /  
 ITEMS 2(d) or 2(e)

-----  
 6 CITIZENSHIP OR PLACE OF ORGANIZATION

SWITZERLAND

	7	SOLE VOTING POWER	
		1,121,353	
NUMBER OF	8	SHARED VOTING POWER	
SHARES		0	
BENEFICIALLY	9	SOLE DISPOSITIVE POWER	
OWNED BY		1,121,353	
EACH	10	SHARED DISPOSITIVE POWER	
REPORTING		0	
PERSON			
WITH			

-----  
 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,121,353

-----  
 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\* / /

-----  
 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

6.8%

-----  
 14 TYPE OF REPORTING PERSON\*

CO, HC

-----  
 \*SEE INSTRUCTIONS BEFORE FILLING OUT!  
 INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7

ITEM 1. SECURITY AND ISSUER. The class of equity securities to which this statement relates is the common stock, .001 par value ("Common Stock"), of Neurocrine Biosciences, Inc., a California corporation ("Neurocrine"). The principal executive offices of Neurocrine are located at 3050 Science Park Road, San Diego, California 92121.

ITEM 2. IDENTITY AND BACKGROUND. This statement is being filed by Ciba-Geigy Limited, a Swiss corporation ("Ciba"). The principal executive offices of Ciba are located at Klybeckstrasse 141, CH-4002 Basle, Switzerland.

Ciba is the publicly owned parent company of a group of affiliated companies, commonly known as the Ciba Group, which was formed in October 1970 by the merger of two established Swiss companies, Ciba Limited and J.R. Geigy S.A. Shares of Ciba are listed for trading on various stock exchanges in Switzerland, including the Zurich Stock Exchange. Companies in the Ciba Group are principally engaged in the research and development, production and worldwide marketing of various kinds of pharmaceuticals and specialty chemicals, as well as electronic equipment.

The name, business address, present principal occupation and citizenship of each executive officer and member of the Board of Directors of Ciba is set forth on Schedule I hereto and is incorporated by reference herein.

Neither Ciba nor, to the best knowledge of Ciba, any of the persons listed on Schedule I hereto, during the last five years, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Certain such matters relating to Ciba-Geigy Corporation, a subsidiary of Ciba, are described in Schedule II hereto and are incorporated by reference herein.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. On May 31, 1996, Ciba acquired 476,191 shares of Common Stock for an aggregate purchase price of \$5,000,000. Ciba had previously acquired 645,162 shares of Common Stock for an aggregate purchase price of \$5,000,000. In each such case, the funds for the acquisitions were obtained from working capital.

ITEM 4. PURPOSE OF TRANSACTION. Ciba has acquired the Common Shares for the purpose of investment. Ciba has an ongoing relationship with Neurocrine in that Ciba and Neurocrine are engaged in a collaborative research and development program.

Except as otherwise indicated in this statement, Ciba does not have any plans or proposals with respect to Neurocrine that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) Ciba beneficially owns 1,121,353 shares of Common Stock, constituting approximately 6.8% of the outstanding Common Stock.

(b) Ciba has the sole power to vote and dispose of all 1,121,353 shares of Common Stock owned by it.

(c) Neither Ciba nor, to the best knowledge of Ciba, any of the persons listed on Schedule I hereto, has effected any transaction in the Common Stock in the past 60 days.

(d) No person other than the record owner referred to herein is known to have the right to receive or the power to direct the receipt of dividends from or proceeds of the sale of shares of Common Stock.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

To the best knowledge of Ciba there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 or between such persons and any other person with respect to any securities of Neurocrine.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

None.

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 10, 1996

CIBA-GEIGY LIMITED

By /s/ Hans F. Mohr

-----  
Name: Hans F. Mohr  
Title: Head of Pharma Licensing

By /s/ Herbert Gut

-----  
Name: Herbert Gut  
Title: Senior Division Counsel

Page 5 of 9 pages.

## SCHEDULE I

Members of the Board of Directors, the Committee of the Board of Directors and the Executive Committee of Ciba-Geigy Limited.

NAME AND BUSINESS ADDRESS	CITIZENSHIP	PRINCIPAL OCCUPATION
Dr. Alex Krauer Chairman and Chief Executive Officer c/o Ciba-Geigy Limited CH-4002 Basle Switzerland	Switzerland	Since 1987: Chairman of the Board of Directors and Member of the Committee of the Board of Directors
Prof. Dr. Helmut Sihler c/o Henkel KGaA D-40191 Dusseldorf Germany	Austria	Since 1983: Member of the Board of Directors  Since 1992: Member of the Committee of the Board of Directors  Since 1993: Vice-Chairman  Retired Chairman of the Central Board of Management of Henkel KGaA, Germany
Birgit Breuel Treuhandanstalt Detiev-Rohwedder-Haus Leipziger Strasse 5-7 D-10100 Berlin Germany	Germany	As of October 1, 1994: Member of the Board of Directors  President of Treuhandanstalt, Berlin
Prof. Max M. Burger c/o Friedrich Miescher Institute P.O. Box 2543 CH-4002 Basle Switzerland	Switzerland/USA	Since 1980: Member of the Board of Directors  Director of Friedrich Miescher Institute, Basle
Kasper V. Cassani C/o IBM Switzerland CH-8002 Zurich Switzerland	Switzerland	Since 1985: Member of the Board of Directors  Since 1994: Member of the Committee of the Board of Directors  Retired Vice-Chairman of IBM Corporation
Dr. William J. Rutter c/o Chiron Corporation 4560 Horton St. Emeryville, CA 94608-2916	U.S.A.	Since 1995: Member of the Board of Directors  Chairman of Chiron Corporation

NAME AND BUSINESS ADDRESS	CITIZENSHIP	PRINCIPAL OCCUPATION
David de Pury c/o ABB ASEA Brown Boveri AG P.O. Box 8131 CH-8050 Zurich Switzerland	Switzerland	Since 1992: Member of the Board of Directors  Co-Chairman of the Board of ABB ASEA Brown Bovari AG, Zurich
Walter G. Frehner c/o Swiss Bank Corporation Aeschenplatz 6 CH-4002 Basle Switzerland	Switzerland	Since 1994: Member of the Board of Directors  Chairman of the Board of Directors of Swiss Bank Corporation
Rainer E. Gut c/o Credit Suisse Paradeplatz CH-8021 Zurich Switzerland	Switzerland	Since 1985: Member of the Board of Directors  Since 1994: Member of the Committee of the Board of Directors  Chairman of the Board of Directors of the Credit Suisse
Prof. Jean-Marie Lehn c/o Institute le Bel University Louis Pasteur 4.rue Blaise Pascal F-67070 Strassbourg cedex France	France	Since 1991: Member of the Board of Directors  Universite Louis Pasteur, Institute le Bel, Professeur au Collage de France a Paris
Michael Ringier c/o Ringier AG Dutourstrasse 23 CH-8008 Zurich Switzerland	Switzerland	Since 1993: Member of the Board of Directors  Chairman of the Board of Ringier AG
Prof. Hugo E.R. Uyterhoeven c/o Harvard University Graduate School of Business Administration Morgan 349 Boston, MA 02163	USA	Since 1980: Member of the Board of Directors  Professor and Senior Associate Dean at Harvard Business School, Boston
Ingrid Duplain c/o Ciba-Geigy Limited CH-4002 Basle Switzerland	Switzerland	Since 1996: Secretary of the Committee of the Board of Directors and the Executive Committee (not a member) Head Central Secretariat

NAME AND BUSINESS ADDRESS	CITIZENSHIP	PRINCIPAL OCCUPATION
Pierre E. Douaze c/o Ciba-Geigy Limited CH-4002 Basle Switzerland	France	1991: Responsible for the Pharma and Self-Medication Divisions, and worldwide Head of the Pharma Division
Dr. Hans Kindler c/o Ciba-Geigy Limited CH-4002 Basle Switzerland	Switzerland	1990: Responsible for Personnel, Production and Technology and Safety and Environmental Protection
Dr. Rolf A. Meyer c/o Ciba-Geigy Limited CH-4002 Basle Switzerland	Switzerland	1992: Chief Financial Officer
Dr. Wolfgang Samo c/o Ciba-Geigy Limited CH-4002 Basle Switzerland	Switzerland	1993: Responsible for the Plant Protection, Animal Health and Seeds Divisions, and worldwide Head of the Plant Protection Division
Dr. Hermann Vodicka c/o Ciba-Geigy Limited CH-4002 Basle Switzerland	Austria	1993: Responsible for the Polymers, Composites, Mettler-Toledo and Ciba-Vision Divisions and worldwide Head of the Polymers Division

Page 8 of 9 pages.



## SCHEDULE II

On February 28, 1992, Ciba-Geigy Corporation ("CGC") and two employees from its Toms River plant pleaded guilty in Superior Court, Law Division, Mercer County, New Jersey, to one count of unintentional illegal disposal of pollutants in a double-lined landfill. Judgment of conviction was entered on March 23, 1992. As part of the settlement agreement, CGC paid a criminal fine of \$3.5 million, civil penalties of \$5.5 million and administrative costs of \$2.35 million. At the same time, it made a contribution to the State of New Jersey of \$2.5 million for environmental purposes.

On August 14, 1992, CGC pleaded no contest in Louisiana State Court, 18th Judicial District, to fifteen misdemeanor counts arising from falsification of certain back-up quality control data relating to water discharge permits at its St. Gabriel plant and paid a \$250,000 fine. At the same time, it made two contributions of \$50,000 each to the Sheriff's offices of Iberville Parish and West Baton Rouge Parish.

In 1992, CGC pleaded guilty to an Environmental Control Complaint and Summons resulting from an odor emission at its Newport, Delaware plant site. The matter was under the jurisdiction of the Delaware Justice of the Peace Court, Newport, Delaware. A fine of \$598.50 was paid.

Page 9 of 9 pages.